Copyright
©The Author(s) 2022.
World J Clin Oncol. Jul 24, 2022; 13(7): 599-608
Published online Jul 24, 2022. doi: 10.5306/wjco.v13.i7.599
Published online Jul 24, 2022. doi: 10.5306/wjco.v13.i7.599
Table 3 Adverse events associated with coronavirus disease 2019 vaccination in published studies
Ref. | Sample size (n) | Cancer type | Systemic therapy | Vaccines administered | Patients with Grade 3 or worse AE, % | Immune-related AEs | Comment |
Oosting et al[23] | 544 | Solid Tumors | Chemotherapy; Immunotherapy; Chemoimmunotherapy | mRNA-1273 (Moderna) | 10/544 (1.8%) | 4% in both immunotherapy and chemoimmunotherapy group | Total 4 serious AEs were potentially related to the vaccination |
Cavann et al[24] | 257 | Solid Tumors | Chemotherapy; Immunotherapy; Chemoimmunotherapy; Chemotherapy plus biological therapy; Biologic therapy | PfizerModerna | 0/257 (0%) | NA | Approximately 1/3rd of patients reported mild local reactions (pain, erythema) at the injection site |
Waissengrin et al[25] | 134 | Solid Tumors | Immune checkpoint inhibitor; Chemoimmunotherapy | BNT162b2 mRNA vaccine (Pfizer) | 0/134 (0%) | Nonattributable to the vaccination | Fatigue (34%), headache (16%), muscle pain (34%) |
Di Noia et al[26] | 816 | Solid Tumors | Chemotherapy; Immunotherapy; Chemoimmunotherapy; Targeted therapy | Pfizer | 3.3% after the 1st dose, 1.4% after the second dose | NA | AE occurred in 359 (44%) and 301 (38.3%) patients after the first and second dose, respectively |
Shmueli et al[27] | 129 | Solid Tumors | Chemotherapy; Immunotherapy; Chemoimmunotherapy; Biological Therapy; Hormonal Therapy; Radiotherapy | Pfizer | 0/129 (0%) | NA | AE was reported by 39% of patients after the first dose and 58% of patients after the second dose- all mild to moderate in severity |
Tamura et al[29] | 120 | Solid Tumor | Chemotherapy; Immunotherapy; Targeted Therapy; Chemoimmunotherapy | Pfizer Moderna | 0/120 (0%); CTCAE was not used | NA | Study limited to patients receiving treatment for lung cancer only. No serious AEs or treatment delay was observed |
Kian et al[28] | 210 | Solid & Non-Solid Tumors | Chemotherapy; Immunotherapy; Chemoimmunotherapy; Biological Therapy; Hormonal Therapy; Radiotherapy; Radio-hormonal; Chemo-biological | Pfizer | 0.004% after 1st dose, 1.9% after the second dose | NA | AE occurred in 65 (31%) and 65 (31%) patients after the first and second dose, respectively. Injection site pain was the most common AE after both doses |
- Citation: Cox RE, Parish M, Oxencis C, Mckenna E, Thapa B, Chakrabarti S. Short term safety of coronavirus disease 2019 vaccines in patients with solid tumors receiving systemic therapy. World J Clin Oncol 2022; 13(7): 599-608
- URL: https://www.wjgnet.com/2218-4333/full/v13/i7/599.htm
- DOI: https://dx.doi.org/10.5306/wjco.v13.i7.599